Investigation of the efficacy of social contribution for patients with NAFLD to motivate to start and continue the treatment.

Investigation of the efficacy of social contribution for patients with NAFLD to motivate to start and continue the treatment. - Investigation of the efficacy of social contribution for NAFLD patients to motivate the treatment.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020592

Enrollment

Registered

2016-01-18

Start date

2015-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD

Interventions

Patients will continue the treatment and differences of paired ALT levels (ALT at every 3 month - ALT at baseline) will be evaluated at every 3 month after registration of this study. 1 IU/L of differ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NAPLD patients with ALT levels were persisting upper 31 IU/L for 1 year or more.

Exclusion criteria

Exclusion criteria: patient with other chronic liver disease. patient with pregnancy. Drug induced fatty liver patient with disease associated with fatty liver (polycystic ovary disease, hypothyroidism, obstructive sleep apnea syndrome, hypopituitarism, hypogonadism, after an operation of pancreaticoduodenectomy)

Design outcomes

Primary

Measure	Time frame
Improvement of NAFLD at 3 years after starting this intervention	—

Secondary

Measure	Time frame
Improvement of ALT levels at 3 month after starting this intervention	—

Countries

Japan

Contacts

Public ContactKazuhito Kawata

Hamamatsu University School of Medicine Department of Internal Medicine II

kawata@hama-med.ac.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026